Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Ferguson

Pulmonary Disease Livonia, MI Medical Doctor

NPI 1922016385 CMS profile 42137

28815 8 Mile Rd, Suite 103, Livonia, MI 48152

Open in the dashboard

General payments

$600,644

611 records reported · program years 2019–2025

Research payments

$9,816

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$934,526 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Gary Ferguson of Livonia, MI is reported in the CMS Open Payments database as having received $600,644 across 611 general payments and $9,816 in research payments paid to them. Separately, studies naming them as principal investigator received $934,526 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 Research $5,995 2
2024 Research $3,821 6
2023 General $19,455 23
2022 General $20,009 14
2021 General $79,970 71
2020 General $180,892 136
2019 General $300,319 367

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Ferguson
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Gary Ferguson were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Gary Ferguson Pulmonary Disease median Middle half National median
2019 $300,319 $377 $109–$1,340 $163
2020 $180,892 $230 $56–$907 $114
2021 $79,970 $269 $68–$1,072 $132
2022 $20,009 $390 $100–$1,457 $149
2023 $19,455 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $251,937 235 payments
  2. AstraZeneca Pharmaceuticals LP $76,785 87 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $68,768 69 payments
  4. Mylan Specialty L.P. $60,423 88 payments
  5. AstraZeneca UK Limited $43,059 43 payments
  6. Boehringer Ingelheim International GmbH $34,572 20 payments
  7. CSL Behring $14,305 7 payments
  8. AstraZeneca AB $13,336 21 payments
  9. Mylan Inc. $10,447 11 payments
  10. Novartis Pharmaceuticals Corporation $10,393 14 payments
  11. Other $16,619 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $335,511 187 payments
  2. Consulting Fee $175,559 79 payments
  3. Travel and Lodging $76,029 174 payments
  4. Food and Beverage $10,685 168 payments
  5. Honoraria $2,820 1 payment
  6. Education $41 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $197,542 186 payments
  2. Yupelri Respiratory and Allergy $52,848 76 payments
  3. STIOLTO $31,602 17 payments
  4. BEVESPI AEROSPHERE $31,146 33 payments
  5. STIOLTO RESPIMAT $23,795 8 payments
  6. YUPELRI Anticholinergics, Inhaled $18,022 23 payments
  7. BREZTRI AEROSPHERE $17,766 18 payments
  8. BREZTRI $16,175 9 payments
  9. ANORO ELLIPTA $15,262 14 payments
  10. Zemaira $14,290 6 payments
  11. Other $66,648 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $8,448 3 payments
  2. Galderma Laboratories, L.P. $1,369 5 payments

Records

619 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record